Cytokine therapy has been significant, with interferon-alpha (IFNα) approved for adjuvant therapy in high-risk melanoma and certain refractory cancers, and high-dose interleukin-2 (HDIL-2) approved for metastatic renal cell carcinoma and melanoma. This evidence concerns the gene IL2 and melanoma.